Our Proprietary Technology
Is a one-of-a-kind nanocatalyst that focuses on enhancing wound healing and protecting chronic wounds from infection.
The nanoparticle catalytic efficiency in wound healing was evaluated in a diabetic animal model. The use of the nanoparticle enhanced the natural healing processes with a faster remodeling stage in the study. The biological effects of the nanoparticle were:
NanoSALV was used to treat a diabetic foot ulcer in a 58-year old male patient. The patient presented type 2 diabetes mellitus with 13 years of evolution. This patient was already scheduled for amputation. In order to avoid the amputation, the patient was included into the clinical trial and treated with NanoSALV. In this case, NanoSALV was successful at treating the diabetic foot ulcer to avoid the already prescribed amputation. After a month of treatment, the necrotic tissue of the toes disappeared presenting complete epithelialization below them. After 2 months of treatment, the injury in the base of the heel was completely clean and had a multiplying granulating tissue. In conclusion, NanoSALV was successful in treating the patient’s diabetic foot ulcer.
NanoSALV has been used to treat patients with severe diabetic foot ulcers. These wounds are commonly infected, had exposed bone and tendon, and had surface areas up to 70 cm2. NanoSALV was applied every 48 hours during the treatment. NanoSALV eliminated all pathogens identified in the wounds and achieved wound closure; avoiding prescribed amputations.
Conducted under ISO10993 standards
Conducted under the AOAC standard, Eliminated Gram(+) & Gram(-) bacteria
NanoTess is a social enterprise commercializing health and decontamination products. Our company is governed by our social mandate to ensure accessibility for all.
Copyright © 2020 NanoTess - All Rights Reserved.